WO2005035051A1 - 携帯用イオン導入器及び薬剤投与方法 - Google Patents
携帯用イオン導入器及び薬剤投与方法 Download PDFInfo
- Publication number
- WO2005035051A1 WO2005035051A1 PCT/JP2003/013079 JP0313079W WO2005035051A1 WO 2005035051 A1 WO2005035051 A1 WO 2005035051A1 JP 0313079 W JP0313079 W JP 0313079W WO 2005035051 A1 WO2005035051 A1 WO 2005035051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- portable
- iontophoresis
- skin
- ion introduction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
Definitions
- the present invention relates to a portable iontophoretic device for iontophoresis of a drug subcutaneously or into a blood vessel, and is a medical method including prevention, treatment, and diagnosis in a subject.
- the present invention relates to an introducer and a drug administration method using the portable iontophoretic device.
- the present invention is, in a broad sense, a medical method including prevention, treatment and diagnosis of a subject.
- a cosmetic method a portable iontophoretic device and a drug for performing iontophoreticde 1 ivery of drugs and beautiful skin components
- iontophoresis is a new and improved system for penetrating the drug subcutaneously and deep into the body by locally and continuously applying iontophoresis to specific parts of the human body. A weak current is passed through the skin and ionized
- iontophoresis of the element itself have been the use of some ions of zinc and copper, which can be used in the treatment of various skin infections, or chloride ions, to alleviate surface scarring.
- drug iontophoresis It also includes vasodilators that can be used for rheumatism and peripheral vascular disease, or local anesthetics that anesthetize the affected or treated area. Gastrointestinal side effects due to ingestion of drugs and side effects and toxicity caused by drugs distributed throughout the body other than the affected area can be avoided by iontophoretic administration of drugs.
- Patent Document 1 An induction treatment system has been developed (Patent Document 1).
- Patent Document 2 Japanese Unexamined Patent Publication (Kokai) 1994-178 8 8 15
- prior art iontophoresis has been largely limited to delivering drugs of a single charge polarity to specific skin sites at relatively low concentrations.
- a satisfactory iontophoretic device with a relatively simple design, economical, and capable of providing safe and continuous drug delivery over a long period of time once it has been applied to the patient has not been developed yet.
- Previous attempts to meet these consumer demands have not proven practical or satisfactory.
- it has not been proven to be effective under relatively large molecular size drugs and high concentration conditions.
- a pH controlling buffer is required as a solvent for dissolving the drug, but it is difficult to control the pH at the applicable skin site.
- the purpose of the present invention is to provide an iontophoretic device that can reduce the size of the power supply unit and the operation unit of the introducer, reduce the size of the operation unit, and reduce the weight and size of the device.
- the specific mode of the device is a mode that allows the drug to penetrate subcutaneously or into the blood vessel most efficiently and does not cause discomfort or side effects to the patient. It also provides an iontophoretic device that is relatively simple in design, simplifies operation, and can be easily used by anyone, regardless of usage conditions. Means for solving the problem
- the present invention has been made in view of the above points, and has as its object the object of the present invention is to provide a portable iontophoretic device formed in a pocket type with a shoulder, a waist and a back. Medium and at least one body selected from the group of thighs.
- the portable iontophoresis device is formed in a portable form by attaching it by means of a belt or the like, and the portable iontophoresis device has an Elliptic R waveform and a frequency of 15 From 0 to 1503 Hz, and equipped with an intermittent plane flow input means, comprising an introduction-side electrode terminal and a contralateral terminal, and the two electrode terminals being a target body part and a contralateral body part. It is an object of the present invention to provide a portable iontophoretic device characterized in that it is formed so that it can be attached to each of them.
- the portable iontophoretic device according to claim 1, wherein the surface of the electrode of the pocket-type iontophoretic device is made of one or more materials selected from the group consisting of a metal material, a nonwoven fabric, and a plastic conductive material. It is to provide
- a pocket type including a drug impregnated pad impregnated, and a zion introduction-side electrode terminal destined for the skin and / or mucous membrane of the body where the blood vessel is located with the drug impregnated pad interposed.
- the drug is held inside the blood vessel by the iontophoresis device
- blood vessels to penetrate drugs by ion introduction using the iontophoresis device formed in the above-mentioned pocket type include cubital fossa, anterior carpal region, facial artery, cervix and anterior cervix, armpits, heart, umbilical cord 4.
- An object of the present invention is to provide a method for administering a drug according to claim 3 or 4, which is a drug that enhances expression.
- the skin is impregnated with a drug-impregnated pad impregnated with a drug that penetrates into organs, organs, and tissues to enhance clinical pharmacological effects.
- the introduction-side electrode terminal of the above-mentioned pocket-type iontophoresis device which is applied to the skin and mucous membrane of the thin skin, and the opposite-side electrode terminal, which is applied to the opposite side of the introduction-side electrode terminal across the organ, organ, or tissue.
- a method for administering a drug characterized by injecting the drug into the organ, organ, or tissue from the surface of the skin and / or mucous membrane for a required time only with a portable iontophoresis device equipped with It is to do.
- the organs, organs, and tissues that are ion-introduced using the above-described pocket-type iontophoresis device are the outer ear, gingiva, oral cavity, heart, lungs, trachea-nasal cavity, vagina, uterus, testicle, anus, wound, It is an object of the present invention to provide the method of administering a drug according to claim 6, wherein the method is inflammation or a lesion site.
- the drugs used for ion implantation using the above-described pocket-type iontophoresis device include contraceptives, dental anesthesia and analgesics, hemorrhoids, rescue wounds-healing drugs, anti-inflammatory pain medications
- the present invention provides the drug administration method according to claim 6 or 7, wherein the drug is a drug that requires seizure suppression—an anti-asthmatic drug, an asthma attack-suppressing drug, etc.—emergency / application at the time of use.
- FIG. 1 is a perspective view showing an example of the present invention.
- FIG. 2 is a perspective view from the back showing an example of the present invention.
- FIG. 3 is a perspective view showing a state in which a suspension bender is provided in one example of the present invention.
- Fig. 4 shows a test of the effective resistance value as a constant current circuit in one example of the present invention. It is a graph of the result of having performed.
- FIG. 5 shows the conditions when a test of the effective resistance value was performed as a constant current circuit in one example of the present invention.
- FIG. 6 shows the specifications of an example of the present invention.
- FIG. 7 shows a waveform of ion introduction in an example of the present invention.
- 1 is a power supply and an operation unit.
- 2 is a switch.
- 3 is a polarity adjustment button.
- 4 is an output adjustment button.
- 5 is an output adjustment dial.
- 6 is a polarity adjustment dial.
- 7 is a suspender.
- the present invention restricts the waveform and frequency to a specific mode and adopts intermittent flat flow, thereby avoiding pain, behavioral restrictions, and infectious diseases caused by injection in a subject, and distributing the drug in blood and specific organs / organs. ⁇ The effect of delivering the drug only to the organization can be obtained.
- the power supply unit and the operation unit are integrated, and a specific mode, that is, a frequency in the range of 1—1—5 01— to 1—5 5 ⁇ ⁇ ⁇ —more preferably ⁇ 5 3 0— ⁇ ———
- the waveform is an Elliptic R wave, and the current is limited to intermittent flat flow, so that the drug can be efficiently delivered to the affected area, and the weight and size can be reduced. It is more convenient to inject small amounts of the drug into blood vessels continuously for a long time, and it is easier to select the time and place for drugs that enhance and enhance clinical pharmacological effects, and for drugs that require acute application. It is possible to introduce the drug, without the need for frequent outpatient visits, and it is possible to avoid the pain, labor, and danger of infection from subcutaneous injection.
- the frequency is preferably in the range of 150 to 150 Hz, more preferably 150 Hz
- the waveform is an Elliptic R wave
- the current is ion-introduced under the condition of intermittent flat flow.
- provitamin C has melanin-induced melanin production inhibition by melanocyte, promotion of collagen stiffness in dermal fibroblasts, suppression of collagen degrading enzyme MMP-2 & -9, and ultraviolet rays of DNA 2
- Protective effects against strand breaks and base damage such as 8-HdG and cell death, s 1 ow—do wn effect and prolonged cell life by provitamin CA sc2P against telomere DNA shrinkage accompanying cell division Effect, protection against cell disruption and cell death by lipid peroxide with altered squalene and ceramide in sebum, increased production of reactive oxygen species found in inflamed and tumored skin, transcription factor NF- / B nucleic acid It has the effect of inhibiting the metastasis of collagen, the activation of collagen degrading enzymes MMP-2, 9, and the reduction of the translocation inhibitor gene nm23.
- the medicinal effects of these plasma-Cs have been discovered in the portable T-introducer of the present invention.
- FIG. 1 is a perspective view showing an example of the present invention.
- FIG. 2 is a perspective view from the back showing an example of the present invention.
- Fig. 1 is a pocket-sized portable iontophore main unit, and 2 is a switch. 3 is an output adjustment button, and the output adjustment is performed in four stages.
- the current is variable and can be up to 3.0 mA.
- the frequency and waveform output are adjusted in four steps using dial 7 in Fig. 2.
- the frequency is 153 Hz
- the waveform is Elliptic R wave
- the current is intermittent flat flow.
- the polarity is + ⁇ one.
- the iontophoresis device has a built-in image so that the set time can be confirmed.
- the power supply will be compatible worldwide and will be charged.
- Reference numeral 5 denotes a pad to be attached to each part of the body or tissue.
- the cord will be hook-type for easy installation.
- the portable iontophoretic device employs a constant current circuit so that a constant intermittent current can flow regardless of the resistance value. Resistance depends on conditions
- Fig. 4 and Fig. 5 are graphs showing the results of the effective resistance test performed on the iontophoretic device as a constant current circuit and the conditions under which the effective resistance test was performed.
- the term “intermittent current” as used in the present invention refers to, for example, a case where seven waveforms having a negative polarity are applied, one waveform having a positive polarity is applied, and thereafter, as shown in FIG.
- the intermittent flat flow was selected to prevent the skin from being charged and to efficiently deliver the drug to the affected area (see Fig. 7).
- the method of application is to use a drug-impregnated pad impregnated with a drug that enhances the clinical pharmacological effect by penetrating into organs, organs, and tissues, and then wound, inflammation, and skin and mucous membrane with thin skin at the lesion site. Apply to the outer ear, gingiva, oral cavity, heart, lungs, trachea, nasal cavity, vagina, uterus, testicle, anus, etc., and one of the electrode terminals of the iontophoresis device to the upper part as the introduction-side electrode terminal. Next, the other electrode terminal of the iontophoresis device is used as a counter electrode terminal, and is addressed to the opposite side of the introduction electrode terminal across the organ, organ and tissue, and both terminals are fixed with an adhesive tape or the like.
- the blood vessels to be ion-introduced by the portable iontophoresis device include cubital fossa, anterior carpal region, arteriole, neck and anterior cervix, armpits, heart, navel, anus, inguinal region,
- One or more blood vessels selected from the group consisting of the medial thigh, popliteal, tarsal, posterior malleolar and posterior malleolar, and the skin impregnated with the drug in the same manner as described above is applied to the skin with a thin skin around it. Address and electrode terminals.
- a holder 17 in FIG. 3 is provided to facilitate carrying the iontophoresis device.
- the suspender 7 can be hung on a body or the like by hanging it on a shoulder or the like, and can be attached and carried by other attaching means.
- the shape of the honilder-the ion introducer-not limited to the example of the main body mounting tube and the material of the trowel-but also includes all those that have the function of suspending the ion introducer body on the body and other mounting functions. .
- a drug that enhances the expression of a clinical pharmacological effect that is more preferably injected continuously into a blood vessel in a small amount over a long period of time than a drug administration by a single injection, such as Vita Min C, provitamin (, vitamin E, provitamin E, anticancer agent, cancer metastasis inhibitor, carcinogenesis inhibitor, immunopotentiator, insulin, hydrid cortisone, progesterone, estradiol, testosterone And so on.
- provitamin vitamin E, provitamin E, anticancer agent, cancer metastasis inhibitor, carcinogenesis inhibitor, immunopotentiator, insulin, hydrid cortisone, progesterone, estradiol, testosterone And so on.
- a drug that needs to be applied acutely as a drug used for iontophoresis by the portable iontophoresis device such as contraceptives, dental anesthesia-analgesics, hemorrhoids, rescue wounds, anti-inflammatory analgesics, heart Use seizure inhibitors, asthma attack inhibitors, etc.
- High Vita 1 iot (manufactured by Indiva Japan) was used as the iontophoresis device.
- the frequency of this product can be changed in three stages (mode 1, mode 2, mode 3) from 50,000 Hz to 153 Hz, and the waveform is also an intermittent flat flow “rectangular wave ”Can be changed mainly by three types of R wave (squarish-R), rectangle R (rectangu 1 ar-R), and Elliptic R wave (mode 1 'mode 2 ⁇ mode 3).
- the solution of Asc '2 ⁇ ' ⁇ a is impregnated into the stratum corneum of the skin piece, and the double gauze is applied to the upper electrode-the introducer-the negative electrode terminal is applied, and the subcutaneous side is the positive electrode terminal
- the measured current value was measured with a multimeter.
- a 4% aqueous solution of Asc2PNa is ion-introduced, and after 4 hours, the skin pieces are separated into epidermis and dermis, and provitamin C and total vitamin C (total of reduced and oxidized vitamin C in each part) ), Oxidized vitamin C (dehydroascorbic acid) was quantified.
- Fig. 6 shows the electrical characteristics of mode 3-3 in High Vita 1 iont (manufactured by Indiva Japan), and Fig. 4 shows the waveforms.
- the vitamin C concentration in the skin was 2240-389 OM in the epidermis, which was 56-97 times higher than that of blood vitamin C.
- the dermis also achieved 1 27-28 1 M. Since topical application barely detects vitamin C in the dermis, the penetration of provitamin by iontophoresis has been greatly increased. Furthermore, while the conventional iontophoresis device had a poor vitamin C reduction rate of 30 to 60%, the frequency of High Vita 1 iont (manufactured by Indiva Japan) was 1503 Hz and the waveform was Elliptic. The R-wave (mode 3-3) was extremely good at 97-100%. Vitamin C reduction rate is an index indicating how vitamin C converted from provitamin C is retained in the form of reduced pharmacologically safe vitamin C.
- the portable iontophoresis device of the present invention limits the frequency and waveform that enable the most efficient iontophoresis to a specific mode, adopts intermittent flat flow, and has a simpler design. It is designed to be smaller and lighter.
- Table 3 shows the specifications of the portable ion implanter as an example of the present invention.
- 1 1-1-----'Asc 2P ⁇ Na of provitamin C (ascorbic acid-2-O-phosphate sodium salt, manufactured by Showa Denko KK) at a concentration of 20%.
- the iontophoresis mode is an Elliptic R-wave waveform of 150 Hz Frequency, 0.3 mA current value, 50% duty ratio, 1: 8 Reversa 1 electrical polarity reset (Table 3).
- the blood vitamin C before the operation was 13.4 ⁇ 0.2 umo 1 ZL, but 1 hour after the operation, 18.5 ⁇ 0.3 umol / L, and 2 hours, 30. 1 soil 1.9 umol / L, below 3, 4, 5, 6, 8, 10, 24 hours 34.2 ⁇ 3.8, 57.0 ⁇ 4.9, 8 3. 3 ⁇ 7.6, 68.9 ⁇ 4.1, 88.9 ⁇ 6.5, 71.0 ⁇ 6.4, 73.1 ⁇ 4.7 umo 1 / L, ideal Blood vitamin C levels were maintained.
- Provitamin E Q! TOCP (Hy-tocopherol phosphate, manufactured by Sigma-Aldrich) is dissolved at a concentration of 8% in 1 mL of pure water (distilled water or Mi11iQ ultrapure water).
- 0 x 3 0 x 5 mm size suction A 31-year-old female impregnated with a water pad is directed to the vein on the flexion side of the right knee.
- the negative electrode terminal of the portable iontophoretic device of the present invention shown in Fig. 1 was applied, and the positive electrode terminal was applied to the outside of the right leg near the foot of the knee, 10 cm outside, and both terminals were connected. It was fixed with adhesive tape.
- the main body of the iontophoresis device was suspended from the waist with a string.
- the iontophoresis mode was an Elliptic R wave waveform with a frequency of 153 OHz, a current value of 0.5 mA, a duty ratio of 50%, and an electrical polarity reset of 1: 8 ReV ersa 1 ( Table 3).
- the blood vitamin E before the operation was 17.5 ⁇ 0.6 umo 1 ZL, but 1 hour after the operation, 19.5 persons 0.4 ⁇ mol ZL and 2 hours, 20.4 ⁇ 3.
- Human insulin (molecular weight: 5807, manufactured by Novo) is purified to a concentration of 100 U / mL, which is more concentrated than normal injection liquid (distilled water or Mi11iQ ultrapure water).
- normal injection liquid distilled water or Mi11iQ ultrapure water.
- a 30 x 30 x 0.5 mm absorbent pad inside a 50 x 50 x xl mm size gel-coated nonwoven Suspend in 1 mL and impregnate a 30 x 30 x 0.5 mm absorbent pad inside a 50 x 50 x xl mm size gel-coated nonwoven, fast for 6 hours, 39 years old, female To the vein at the back of the right side.
- the negative electrode terminal of the portable iontophoresis device of the present invention shown in Fig. 1 is addressed to this pad, the positive electrode terminal is addressed 5 cm outside from the right shoulder to the elbow, and both terminals are fixed with adhesive tape. did.
- the body of the ion introducer was hung on the right side with a string over the shoulder.
- the introduction mode was performed with an Elliptic R wave waveform at a frequency of 153 OHz, a current value of 0.7 mA, a duty ratio of 50%, and an electrical polarity reset of 1: 7 ReV ersa 1 (Table 3).
- the blood insulin level before the administration was 11.5 ⁇ 0.6 U / mL, but 1 hour after the administration, 13.5 soil 0.4 umo 1 ZL, 2 hours, 20.4 ⁇ 3.0 umo 1 ZL, below, 3, 4, 5, 6, 8, 10 and 24 hours 23.0 ⁇ 7.1, 36.1 ⁇ 1.0, 27.2 ⁇ 4.6, 32.9 ⁇ 5.9, 30.8 ⁇ 5.4, 33.7 ⁇ 6.4, 28.0 ⁇ 3.4 umo 1 ZL, ideal blood sample Concentration could be maintained.
- the measurement of insulin in the blood was performed by Radioimnoassy. This measurement was consistent with the results of the ODS column HPLC (high performance liquid chromatography) and UV flow detector.
- the local anesthetic, Lidocaine Hydrochloride was added to a concentration of 50 mg ZmL, which was more concentrated than the Xylocaine intravenous injection (100 mg Lidocaine / 5 mL) manufactured by Fujisawa Pharmaceutical Co., Ltd. MT1 ⁇ —i Q ultra-pure water) lm Lt was dissolved, and 0.4 mL of the solution was impregnated into a 1 O x 10 x 2 mm water-absorbing pad.
- the lower teeth and gingiva extracted from the 8-week-old Wister rat were organ-cultured by soaking the root side in DMEM medium, and a pad was applied to the ⁇ -side gingiva of the front teeth.
- the positive electrode terminal of the portable iontophoresis device of the present invention shown in Fig. 1 is addressed to this pad, and the negative electrode terminal is addressed to the pharyngeal gingiva of the anterior teeth, and both ends are temporarily fixed together with the teeth by connecting clips. did.
- the main body of the iontophoresis device is placed outside the organ culture, but in actual medical practice, it can be hung with a belt around the shoulder or neck of the patient.
- the ion introduction mode is a waveform of Elliptic R wave, frequency of 153 OHz, 0.
- the test was performed with a current value of 5 mA, a duty ratio of 50%, and an electrical polarity reset of 1: 7 ReVersa1 (Table 3).
- the gingiva was excised to 5 ⁇ 5 mm on the ⁇ side, and sliced into 4 m thick sections using a cryostat. Approximately 100 slices were collected in order from the gingival surface, separated into five fractions at approximately 400 zm depth, weighed, frozen and thawed with liquid nitrogen, and gingival braided with Vortex Mixer. The weave was crushed. Lidocaine was recovered from the crushed liquid of each fraction by ethanol extraction, separated by HPLC on a DS column, and measured with a UV flow detector.
- the concentration of lidocaine in the gingiva was 76.2 ⁇ 8.2 nmo 1 / gtis 3 116, the fraction up to 400 4 1 from the surface, 400 -8 001 fraction 4.3.0 ⁇ 1 1.2 nm o 1 / gtissue, 800-1 200 zm fraction 39.4 ⁇ 7.0 nmo ⁇ / gtissue, 1 200-1 600 zm fraction 2 4.5 ⁇ 8.9 nmol / gtissue, 1600-1200 m fraction 11.3 ⁇ 0.8 nm o1 / gtissue, showing a depth distribution, sufficient for the tissue area where nerves are distributed It was shown that local anesthesia in a short time passed painlessly and without bleeding.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005509470A JP4217984B2 (ja) | 2003-10-10 | 2003-10-10 | 携帯用イオン導入器 |
AU2003271179A AU2003271179A1 (en) | 2003-10-10 | 2003-10-10 | Portable ion introduction unit and method for dosing medicine |
PCT/JP2003/013079 WO2005035051A1 (ja) | 2003-10-10 | 2003-10-10 | 携帯用イオン導入器及び薬剤投与方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/013079 WO2005035051A1 (ja) | 2003-10-10 | 2003-10-10 | 携帯用イオン導入器及び薬剤投与方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005035051A1 true WO2005035051A1 (ja) | 2005-04-21 |
Family
ID=34430865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013079 WO2005035051A1 (ja) | 2003-10-10 | 2003-10-10 | 携帯用イオン導入器及び薬剤投与方法 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4217984B2 (ja) |
AU (1) | AU2003271179A1 (ja) |
WO (1) | WO2005035051A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014054459A1 (ja) * | 2012-10-05 | 2014-04-10 | 株式会社資生堂 | 美容機器、通電方法及び記録媒体 |
US9795783B2 (en) | 2010-11-09 | 2017-10-24 | Shiseido Company, Ltd. | Content reproduction apparatus, content reproduction method, and storage medium |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014068698A1 (ja) * | 2012-10-31 | 2014-05-08 | 株式会社インディバ・ジャパン | 脂肪滴・セルライト抑制装置 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02241464A (ja) * | 1989-03-16 | 1990-09-26 | Advance Co Ltd | イオントフォレーゼ用デバイス |
JPH09103496A (ja) * | 1995-10-12 | 1997-04-22 | Etsuko Nozoe | イオン浸透治療器 |
WO2000074774A1 (en) * | 1999-06-09 | 2000-12-14 | Africa Antonino D | Ionophoretic drug delivery device |
JP2001212248A (ja) * | 1999-12-09 | 2001-08-07 | Iomed Inc | イオン浸透療法用薬剤送達装置のための連結鎖を含む接続システム |
-
2003
- 2003-10-10 AU AU2003271179A patent/AU2003271179A1/en not_active Abandoned
- 2003-10-10 JP JP2005509470A patent/JP4217984B2/ja not_active Expired - Lifetime
- 2003-10-10 WO PCT/JP2003/013079 patent/WO2005035051A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02241464A (ja) * | 1989-03-16 | 1990-09-26 | Advance Co Ltd | イオントフォレーゼ用デバイス |
JPH09103496A (ja) * | 1995-10-12 | 1997-04-22 | Etsuko Nozoe | イオン浸透治療器 |
WO2000074774A1 (en) * | 1999-06-09 | 2000-12-14 | Africa Antonino D | Ionophoretic drug delivery device |
JP2001212248A (ja) * | 1999-12-09 | 2001-08-07 | Iomed Inc | イオン浸透療法用薬剤送達装置のための連結鎖を含む接続システム |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9795783B2 (en) | 2010-11-09 | 2017-10-24 | Shiseido Company, Ltd. | Content reproduction apparatus, content reproduction method, and storage medium |
WO2014054459A1 (ja) * | 2012-10-05 | 2014-04-10 | 株式会社資生堂 | 美容機器、通電方法及び記録媒体 |
JP2014073332A (ja) * | 2012-10-05 | 2014-04-24 | Shiseido Co Ltd | 美容機器及び通電方法及び記録媒体 |
CN104684612A (zh) * | 2012-10-05 | 2015-06-03 | 株式会社资生堂 | 美容设备、通电方法及记录介质 |
US9981125B2 (en) | 2012-10-05 | 2018-05-29 | Shiseido Company, Ltd. | Cosmetic device, method of applying current, and storage medium |
Also Published As
Publication number | Publication date |
---|---|
AU2003271179A1 (en) | 2005-04-27 |
JPWO2005035051A1 (ja) | 2006-12-21 |
JP4217984B2 (ja) | 2009-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6238381B1 (en) | Iontophoretic treatment system | |
EP0776676B1 (en) | Ionophoretic treatment system | |
JP6092469B2 (ja) | 拡張可能な創傷被覆材 | |
US6738663B2 (en) | Implantable device and method for the electrical treatment of cancer | |
Harris | Iontophoresis: clinical research in musculoskeletal inflammatory conditions | |
JP2000510012A (ja) | イオン導入法による薬剤の供給装置およびその使用方法 | |
US20020173743A1 (en) | Iontophoretic treatment system | |
JP2005329246A (ja) | フェンタニール及びスフェンタニールの経皮電気的移送式投与デバイス | |
AU2012282862A1 (en) | System for wound healing | |
JP2001505197A (ja) | リドカイン及びエピネフリンの電気的補助投与のための製剤 | |
EP2037860A2 (en) | Methods for the treatment of wounds | |
Fontanella et al. | Bladder and urethral anaesthesia with electromotive drug administration (EMDA): a technique for invasive endoscopic procedure | |
WO2005035051A1 (ja) | 携帯用イオン導入器及び薬剤投与方法 | |
US6139537A (en) | Iontophoretic treatment system | |
UA78672C2 (en) | Method for preparation and use of conductive medicinal substance (variants) | |
US6235013B1 (en) | Iontophoretic treatment system | |
EP2874693A1 (en) | Electric-field assisted administration of tapentadol | |
Dehghan et al. | Advances in iontophoresis for drug delivery | |
US6600950B1 (en) | Iontophoretic treatment system | |
RU2055568C1 (ru) | Способ коррекции эректильной дисфункции и устройство для его осуществления | |
CN113332042B (zh) | 一种导电网络-硅酮复合智能疤痕贴及其制备方法 | |
JP2005135712A (ja) | 人体アース装置 | |
JP5785657B2 (ja) | 脂肪滴・セルライト抑制装置 | |
RU2157257C1 (ru) | Способ лечения заболеваний заднего отрезка глаза человека методом эндоназального электрофореза и установка для его осуществления | |
Anisimov et al. | Development of a portable device for iontophoresis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2005509470 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003271179 Country of ref document: AU |
|
122 | Ep: pct application non-entry in european phase |